Salute e Benessere

Galapagos receives transparency notification and 13D filing from Tang Capital

Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital. Pursuant to Belgian transparency legislation 1, Galapagos received a transparency notification on February 14, 2025 on behalf of Mr. Kevin Tang, Tang Capital Management, LLC (“ TCM ”), Tang Capital Partners, LP (“ TCP ”), Tang Capital Partners International, LP (“ TCPI ”), and Tang Capital Partners III,...
Nasdaq GlobeNewswire
17/02/2025

Global Market for Rare Disease Diagnostics to Grow at 9.9% CAGR

This report offers quantitative and qualitative data in order to help readers develop business strategies, understand the market landscape, and make informed decisions about rare disease diagnostic products and services. The report covers molecular genetics, cytogenetics, and biochemical testing techniques. It includes market data for 2023 and forecasts for 2024 to 2029, segmented by analysis platform, target, disease class, test purpose, and region. It discusses the market drivers, restraints…
PR Newswire
17/02/2025

News on Richard Wolf/Photocure Collaboration: Interim Flexible BLC solution…

The interim set up does not replace the optimized high-definition solution that is under development. Yet it can serve an unmet need in bladder cancer, giving urology centers the option of using blue light flexible cystoscopy, for example in surveillance, until the new flexible HD scope becomes available. Photocure and Richard Wolf will work with centers interested in purchasing the add-on equipment, including delivery, set-up and training to utilize the interim solution. The interim set up...
PR Newswire
17/02/2025

RAMSAY SANTE : closing repricing 250217

PRESS RELEASE Paris, 17 February 2025 Ramsay Santé has successfully repriced its €1,025m TLB4 and extended for 2 years its €425m TLB3, both merged in a new single Term Loan B5Ramsay Santé today announced that it has repriced its €1,025m TLB4 from E+4.00% to E+3.25% / 100 OID (same maturity, i.e. August 2031). Simultaneously, the group has extended for 2 years the maturity of its former €425m TLB3 from August 2029 to August 2031 (same margin, i.e. E+3.25%)...
Nasdaq GlobeNewswire
17/02/2025

Virbac : Declaration of the number of shares and voting rights 01/2025

DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers)Place cotation : Euronext Paris Compartiment A Code ISIN : FR0000031577DATENombre total d'actionscomposant le capital socialNombre total de droits de vote31 Janvier 20258 390 660Total brut de droits de vote : 12 706 430Total net* de droits de vote :...
Nasdaq GlobeNewswire
17/02/2025

CanSinoBIO to Showcase China's Vaccine Innovation at 2025 World Government…

CanSinoBIO's participation in the summit represents a significant milestone in its global expansion, highlighting its commitment to global public health. By engaging with global leaders, the Company aims to showcase its growing influence, strengthen its biopharma position, and drive innovation and collaboration for a positive global impact. CanSinoBIO's participation in the summit represents a significant milestone in its global expansion, highlighting its commitment to global public health...
PR Newswire
17/02/2025

Benign Prostatic Hyperplasia Surgical Treatment Market to Hit USD 17.19 Billion…

Browse in-depth TOC on "Benign Prostatic Hyperplasia Surgical Treatment Market" Browse in-depth TOC on "Benign Prostatic Hyperplasia Surgical Treatment Market" 368 - Tables 59 - Figures 328 - Pages Based on drug type, the global Benign Prostatic Hyperplasia Surgical Treatment market can be divided into three segments: alpha-blockers (α-blockers), 5-alpha reductase inhibitors (5-ARIs), and other drug types [combination drugs, muscarinic receptor antagonists (MRAs), and...
PR Newswire
17/02/2025

SHEIN SPREADS SMILES WORLDWIDE WITH LAUNCH OF NEWMOJI® AND SMILEYWORLD®…

"We're thrilled to launch a new range of Newmoji® products with SHEIN and build on the SmileyWorld® product offering," said Janet Wilson, Chief Product Officer – Lifestyle Consumer Products at The Smiley® Company. "This collection centers on fun and positivity, allowing customers to express their emotions and individuality. SHEIN is a fantastic partner with a vast global reach, and we can't wait to see how people engage with these products." "We're thrilled to launch a…
PR Newswire
17/02/2025

TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the…

U.S. Apixaban sales reached $26.1 billion in 2024*, and the global anticoagulant market continues to expand. Given these trends, TAH3311 is well positioned as a safer and more accessible treatment option. TAHO Pharmaceuticals plans to file regulatory submissions in both the United States and Europe in Q3 2025. At the same time, the company is actively pursuing strategic collaboration opportunities with international partners to accelerate TAH3311's global launch.*Source: IQVIA 2024 U.S...
PR Newswire
17/02/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS 17 FEBRUARY 2025 at 15.15 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 14 February...
Nasdaq GlobeNewswire
17/02/2025

Endo Launches "Steve's Journey," the First Branded Dupuytren's Contracture…

"Those with the best understanding of Dupuytren's contracture are patients who have faced similar challenges and uncertainties," said Justin Mattice, Vice President & General Manager, Branded Specialty at Endo. "By spotlighting authentic experiences like Steve's, we are emboldening patients to connect with a hand specialist and ask for nonsurgical XIAFLEX®, positioning them as knowledgeable decision makers." "Those with the best understanding of Dupuytren's…
PR Newswire
17/02/2025

3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as…

In this newly published study, researchers at 3Z, integrated cross-species behavioral assays, Mendelian Randomization analysis, and human genetic data to demonstrate amlodipine's therapeutic potential. Key findings include: In this newly published study, researchers at 3Z, integrated cross-species behavioral assays, Mendelian Randomization analysis, and human genetic data to demonstrate amlodipine's therapeutic potential. Key findings include: Dr.Karl Karlssona neuroscientist, CEO of 3Z...
PR Newswire
17/02/2025

Stryker launches ProCeed hospital bed

Over the last several years, nursing staff turnover has increased, and a significant percentage of frontline nurses across the globe have considered leaving their roles1. As hospitals continue to face nursing shortages and staff burnout2, patient care equipment, like beds, need to endure a heavy workload and provide staff with a straightforward experience. ProCeed was built to withstand the demands of healthcare and provide staff with a durable and cleanable hospital bed. Over the last…
PR Newswire
17/02/2025

The Galien Foundation Announces New Prix Galien UK Award Category for "Best…

The Galien Foundation has been pleased to work with Trinity Life Sciences who have applied their health equity and life sciences expertise to shaping this new category. By introducing this category, the Prix Galien UK Committee aims to encourage both the life science industry and public institutions to pursue ground-breaking work that can lead to an improvement in equitable access to the health innovations that countless scientists deliver. The Galien Foundation has been pleased to work with...
PR Newswire
17/02/2025

GN Store Nord A/S - Notice to convene the Annual General Meeting 2025

GN Store Nord's Annual General Meeting will be held on Wednesday, March 12, 2025, at 10:00 a.m. CET at the company's address: Lautrupbjerg 7, 2750 Ballerup, Denmark.Please find attached the notice to convene the Annual General Meeting, including the agenda and complete proposals. For further information, please contact:Investor RelationsRune Sandager +45 45 75 92 57 Media Relations Steen Frentz Laursen +45 20 65 34 20 About GN GN facilitates communication between people...
Nasdaq GlobeNewswire
17/02/2025

Baltics leading pharmaceutical company Grindeks expands to new export markets…

Kirovs Lipmans, Chairman of the Council of Grindeks, highlights: "Expanding into new export markets is a testament to our long-term vision and dedication to global healthcare. By continuously investing in innovation, quality, and regulatory excellence, we ensure that Grindeks remains a trusted name worldwide. Our presence in diverse markets reflects our commitment to providing effective and accessible medicines to those who need them most." Kirovs Lipmans, Chairman of the Council of…
PR Newswire
17/02/2025

Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in…

The study looked at 2,854 NMIBC* patients from the US Blue Light Cystoscopy with Cysview Registry. A total of 201 (7%) patients had at least one malignant lesion detected exclusively by BLC while having a negative WLC. These lesions (335 in total) included carcinoma in-situ (CIS) (145; 43%), low-grade Ta in (53; 16%), high-grade Ta in (95; 28%), high-grade T1 (37; 11%), and high-grade T2 (5; 1%). As a result of BLC-enhanced detection, the rate of upgrading or upstaging to a more advanced tumor…
PR Newswire
17/02/2025

Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons…

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers.On track for commercial launch in the U.S. in the first half of 2025.A Tropical Disease Priority Review Voucher was awarded to the Company upon approval.COPENHAGEN, Denmark, February 14, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Food and Drug Administration (FDA) has approved VIMKUNYA™ (Chikungunya Vaccine,...
Nasdaq GlobeNewswire
14/02/2025

GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the…

In conjunction with (i) the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, and (ii) the final terms of the dual proposal to the 2025 OCEANEs holders announced on February 10, 2025, GENFIT will seek the consent of the holders of 2025 OCEANEs and proposes to amend such final terms so as to:repurchase the 2025 OCEANEs at EUR 32.75 per bond from interested bondholders, or alternativelypay a consent fee of EUR 0.90 per bond still outstanding after...
Nasdaq GlobeNewswire
14/02/2025

CE Mark Approval for RemeOs™ Trauma Screw Product Group, featuring four product…

The CE mark approval received in January 2025 opens market access across Europe, where the product now complies with the stringent MDR (Medical Device Regulation) requirements of the European Economic Area. This comprehensive approval encompasses all product lines within the RemeOs™ group, meeting diverse surgical needs across various indications for both adult and pediatric patients. The approved indications include the treatment of epi-/metaphyseal bone fractures (osteosynthesis) and the use…
PR Newswire
14/02/2025

Bioretec Ltd's Financial Statements 2024 published

Further enquiries Further enquiries Alan Donze, CEO, +1 619 977 5285Johanna Salko, CFO, +358 40 754 8172 Certified adviser Nordic Certified Adviser AB, +46 70 551 67 29 Bioretec in brief Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of absorbable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture...
PR Newswire
14/02/2025

Microcarriers Market to Hit USD 3.05 Billion by 2029 with 8.0% CAGR |…

Browse in-depth TOC on "Microcarriers Market" Browse in-depth TOC on "Microcarriers Market" 761 - Tables57 - Figures557 - Pages Based on product, the microcarriers market is segmented into consumables and equipment. The consumables segment accounted for the largest share of the microcarriers market. The large share of the consumables segment is attributed to the repeated purchase and requirement in bulk quantities of sera, media, and reagents for various microcarrier...
PR Newswire
14/02/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS 14 FEBRUARY 2025 at 16.15 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 13 February...
Nasdaq GlobeNewswire
14/02/2025

Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum stockholders' equity requirement Evaxion has restored its equity above the minimum requirement through capital market activitiesEvaxion's cash runway now extends to mid-2026The conversion of Evaxion's EIB loan to equity is still expected to be completed in Q1 2025, which is anticipated to further boost equityCOPENHAGEN, Denmark, February 14, 2025 - Evaxion Biotech A/S...
Nasdaq GlobeNewswire
14/02/2025
Altri  Comunicati